Key Points Axsome Therapeutics has launched exciting new drugs over the past year, and they are delivering growth. The biopharma player’s late-stage pipeline could translate into additional products over the next few years. 10 stocks we like better than Axsome Therapeutics › Axsome Therapeutics (NASDAQ:AXSM) has seen its stock price climb over the past few years -- and for good reason. The company has progressively launched new products, confirming its expertise in the neuroscience space. This biotech aims to treat a variety of conditions linked to central nervous system (CNS) operations, from depression to migraine and narcolepsy.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.